Enhanced liver fibrosis scoreBiomarker2 papersLatestNov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 1Oct 2026: 02CureusReview·2 OctFibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular DiseaseMechanismsJournal of HepatologyReview·29 SepEASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted TherapyIndustry & policy
CureusReview·2 OctFibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular DiseaseMechanisms
Journal of HepatologyReview·29 SepEASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted TherapyIndustry & policy